Vitamin K Epoxide Reductases
"Vitamin K Epoxide Reductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.
| Descriptor ID |
D064417
|
| MeSH Number(s) |
D08.811.682.690.708.961
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vitamin K Epoxide Reductases".
Below are MeSH descriptors whose meaning is more specific than "Vitamin K Epoxide Reductases".
This graph shows the total number of publications written about "Vitamin K Epoxide Reductases" by people in this website by year, and whether "Vitamin K Epoxide Reductases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vitamin K Epoxide Reductases" by people in Profiles.
-
Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol. 2021 Aug; 166(8):2089-2108.
-
Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLoS Comput Biol. 2021 03; 17(3):e1008805.
-
Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism as determinant of differences in Covid-19-related disease severity. Med Hypotheses. 2020 Nov; 144:110218.
-
Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin. Hepatol Int. 2019 Mar; 13(2):214-221.
-
Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018 09; 84(9):1868-1882.
-
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. Eur J Clin Invest. 2018 Jun; 48(6):e12929.
-
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial. Eur J Clin Pharmacol. 2018 May; 74(5):571-582.
-
Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. Drug Metab Pers Ther. 2017 12 20; 32(4):183-190.
-
Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population. Pharmacogenet Genomics. 2017 05; 27(5):210-211.
-
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine (Baltimore). 2016 Dec; 95(52):e5451.